Robert Fenstermaker, MD

Specialty: Neurosurgery
Director, Neuro-Oncology Program
Chair, Department of Neurosurgery

 Request an Appointment
Locations

Roswell Park Main Campus
1-800-ROSWELL (1-800-767-9355)

Dr. Fenstermaker is a Buffalo Spree Top Doctor! Top Doctors 2025 See all of our physicians who made this year's list.

Cancers Treated:

Brain

Specializing In:

  • Brain Tumor Surgery
  • Skull Base Surgery
  • Pituitary Tumor Surgery
  • Trigeminal Neuralgia
  • Gamma Knife Radiosurgery

Research Interests:

  • Immunotherapy for the treatment of malignant brain tumors

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Neurosurgery and Oncology
  • Director, Neuro-Oncology Program
  • Chair – Department of Neurosurgery

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

Background

Education and Training

  • MD - Northeast Ohio Medical University, Rootstown, OH

Residency

  • University Hospitals of Cleveland and Case Western Reserve University School of Medicine, Cleveland, OH

Fellowship

  • Case Western Reserve University School of Medicine (Biochemistry and Pharmacology) Cleveland, OH

Board Certification

  • Neurological Surgery, American Board of Neurological Surgery
What is Cushing's disease? Glioblastoma vaccine clinical trial: Cassandra's story On the fast track to life-changing treatments National spotlight for a homegrown innovation Oligodendroglioma: Josh’s story Surviving a benign brain tumor: Peter’s story Is meningioma cancer? New Surgical Technology Gives Neurosurgeons a Sharper, Broader View Does brain cancer run in families? Roswell Park Launches Immunotherapy Clinical Trials for Multiple Myeloma Low-Grade Glioma Buffalo Goes Gray for Brain Cancer Research If a Brain Tumor is Not Cancerous, Why Do Anything About It? Understanding Brain Tumors: The Basics Clyde's Story: Surviving a Cancerous Brain Tumor What Is "Orphan Drug Status?"

Featured on CancerTalk

What is Cushing's disease?
pituitary tumor
Glioblastoma vaccine clinical trial: Cassandra's story
Cassandra, a Roswell Park patient with brain cancer, walking in a park with her family.
On the fast track to life-changing treatments
Drs Fenstermaker and Ciesielski

Showing all3 of 16

Publications

  Full Publications list on PubMed
  1. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J 3rd, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345.
  2. Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016 Nov;65(11):1339-1352.
  3. Rivers C, Tranquilli M, Prasad S, Winograd E, Plunkett RJ, Fenstermaker RA, Fabiano AJ, Podgorsak MB, Prasad D. Impact of the Number of Metastatic Tumors Treated by Stereotactic Radiosurgery on the Dose to Normal Brain: Implications for Brain Protection. Stereotact Funct Neurosurg. 2017;95(5):352-358.
  4. Galbo PM Jr, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017 Oct 10;8(70):114722-114735.
  5. Fenstermaker RA, Figel SA, Qiu J, Barone TA, Dharma SS, Winograd EK, Galbo PM, Wiltsie LM, Ciesielski MJ. Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res. 2018 Jun 1;24(11):2642-2652.
  6. Figel S, Fenstermaker RA. Cell Cycle. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition. San Diego: Academic Press, 2018: 257-267.